

Detection of *Bla_{oxa-23}* and *bla_{oxa-51}* Genes in MDR *Acinetobacter baumannii* isolated from Different Clinical Sources in Baquba Teaching Hospital in Diyala City, Iraq

Dina D. Salman¹ and Izdehar M. Jasim^{2,a}

^{1,2}Department of Biology, Science College, University of Diyala, Iraq

Emails: izdehar@uodiyala.edu.iq, dinadawood2005@gmail.com

^{a)} Corresponding author: izdehar@uodiyala.edu.iq

Abstract. *Acinetobacter baumannii* is a nosocomial pathogenic bacteria that is increasingly important also mainly affects ill people. In the present research, *bla_{OXA-23}* and *bla_{OXA-51}* genes have been observed in *A. baumannii* clinical MDR isolates. Methodology: From 22 *A. baumannii* isolates, separate clinical specimens were collected from (burns, wounds, blood, urine and fluids) at Baqubah Teaching Hospital. The isolates were biochemically identified and confirmed it by the compact device VITEK 2. The resistance of isolates against antibiotics was tested using the procedure of disc diffusion for all of the following antibiotics (Amikacin, Ampicillin sulbactam, Ceftazidime, Ceftraxone, Ciprofloxacin, Colistin sulphate, Doxycycline, Imipenem, Levofloxacin, Meropenem, Polymyxin B, Trimethoprim Sulfamethoxazole). In order to identify *bla_{OXA-23}* and *bla_{OXA-51}* genes, conventional polymerase chain reaction (PCR) was accomplished. Results: This study found that of 22 isolates 11 (50%) isolated from burns, 5 (22.7%) blood, 3 (13.6%) wounds, 2 (9%) urine and 1 (4.5%) fluids. The current study showed that there was high resistance (100%) to antibiotics (Amikacin, Ciprofloxacin and Levofloxacin) while the resistance of isolates toward antibiotics (Ampicillin sulbactam, Ceftraxone, Doxycycline, Imipenem, Meropenem, Trimethoprim sulfamethoxazole) were (95%, 81%, 90%, 40%, 86%, 90% and 77%), respectively. Whereas resistance to polymyxin B and colistin showed 0%. *Bla_{OXA-51}* was detected in 22 (100%), while *bla_{OXA-23}* was detected in 18 isolates (81%). Conclusion: The study showed a high prevalence of *bla_{OXA-23}* and *bla_{OXA-51}* genes among *A. baumannii* isolates which highlighted the importance of molecular study in order to find the appropriate management and to avoid their spreading during the hospital location.

Keywords: *A. baumannii*, *bla_{oxa23}*, *bla_{oxa51}*, Antibiotic

INTRODUCTION

Acinetobacter baumannii is an opportunistic coccobacillus pathogen, a major source of external health-related infections (1). *A. baumannii* is strictly aerobic, a non-fermentative, non-motile, non-pigmented, catalase positive also oxidase-negative. (2). *Acinetobacter baumannii* and other pathogenic *Acinetobacter* spp. are important sources of nosocomial infections (skin or soft tissue infections, pneumonia, bloodstream infection, urinary tract infection, meningitis) (3). *Acinetobacter baumannii* may acquire multiple antimicrobial resistance pathways, leading to multi-resistant phenotype in certain instances (4). Infections caused by the multidrug-resistant bacteria are the suggested candidates for the treatment using carbapenem antibiotics (5). The drugs of choice for the treatment of serious nosocomial infections caused by *A. baumannii* are carbapenems (6). However, resistance to carbapenem is gradually becoming a great worry, mainly among the nosocomial strains belonging to (ESKAPE) group of pathogenic species (7). CRAB product of carbapenemases and is due to the carbapenem-hydrolysing class D β -lactamases. The OXA-type carbapenemases, which belong to class D β -lactamases are classified into five subgroups. Four of them are acquired carbapenemases, which include (OXA-23, OXA-24, OXA-58, OXA-143), the OXA-51 only one is intrinsic to *A. baumannii* (8). The *bla_{OXA-23}* gene is one of the most prevalent β -lactamase genes on the genome (mostly on the plasmids) of carbapenem-resistant *A. baumannii*. Specific and rapid identification of *A. baumannii* and the strains harboring *bla_{OXA-23}* gene, will suggest referential information on the therapeutic and control defenses for the nosocomial infections owing to the (CRAB). (1,9)

The purpose of this report is to investigate the OXA-51 and OXA-23 among multidrug-resistant *A. baumannii* strains, isolated from different clinical specimens in Diyala City, Iraq.

Methods

Collection of Specimens and identification of isolates :

During the period from September (2020) to March (2021) we collected 22 isolates of *A. baumannii* from clinical specimens of (burns, wounds, urine, blood also fluids) at Baquba Teaching Hospital, Bacteriology lab. The isolates were cultured on MacConkey agar (MA) and blood agar (Merck, Germany) incubated at 37°C in 24 hours. and identified by using biochemical tests like (sugar fermentation, motility, usage of citrate, urease, O/F, catalase, oxidase; growth potential of 37 °C also 42 °C) (10). The identification was confirmed by VITEK 2 automated a device (bioMérieux, France) .

Antimicrobial susceptibility profiles:

The antimicrobial Susceptibility testing was performed based on Kirby-Bauer disk diffusion method according to Clinical Laboratory Standard Institute guidelines (CLSI)(11). Against 12 antibiotic disk (Bioanalyse/TURKEY): (Amikacin (30 mg), ampicillin/sulbactam (20 mg), ceftazidime (10 mg), , Ceftraxon (10 mg) , Ciprofloxacin (5 mg), Colistinsulphate(25 mg), Doxycycline (30 mg), Imipenem (10 mg), Levofloxacin (5 mg), Meropenem (30 mg) and Polymyxin B(300 mg) .

Genomic DNA Extraction :

Extraction of DNA from 22 isolates *A. baumannii* and the concentration of DNA were calculated using a commercial purification method (Genomic DNA purification Kit, promega, USA).

Detection of *bla*OXA-23 and *bla*OXA-51 by polymerase chain reaction analyze (PCR)

In order to investigate of *bla*_{OXA-23} and *bla*_{OXA-51} genes , The primers used in current study shown in “TABLE 1” 12.5 l Master mix (MgCl₂, dNTPs, PCR buffer, also Taq polymerase), 2 l DNA sample, 0.5 l per primary, and 9.5 l PCR reaction mixture (25 l). Cycler ThermalCycler to amplify genes (Bio-Rad Laboratories). Initial denaturation (94°C for 5 minutes), then 30 denaturation cycles (94°C for 30 seconds) and even annealing (54°C and 58°C for 30 seconds for *bla*OXA-23 and *bla*OXA-51 respectively) were used in the PCR. The extension time (72°C for 45 seconds), accompanied by the final extension (72°C for 7 minutes) at the conclusion of the cycling (12,13). A 1.5% agarose gel stained with ethidium bromide was used to separate the PCR products (EtBr). For the image, the gel was visualized using a gel documentation scheme (UVTEC Cambridge, UK). (12,13)

TABLE 1. The primers used in this research

Primers	Oligonucleotide Sequences (5' - 3')	Product Size, bp
<i>bla</i> OXA-23 F:	5'-GATCGTTGGAGAACCAGA-3'	501
<i>bla</i> OXA-23 R:	3'-ATTCTGACCGCATTTCAT5'	
<i>bla</i> OXA-51 F:	5'-TAA TGC TTT GAT CGG CCT TG 3'	353
<i>bla</i> OXA-51 R:	5'-TGG ATT GCA CTT CAT CTT GG 3'	

Results

Susceptibility To Antibiotics profiles

Resistance to 12 antimicrobial agents was found among high percent of *A. baumannii* isolates. Resistance to

(amikacin, Ciproflaxacin, and Levoflaxacin) was 100%, while resistance to (Ampicillinsulbactam, Ceftazidme, Ceftraxon, Doxycylin, Impenem, Meropenem, Trimetheprim and Sulfomethazol) were 95 %, 81 %, 90 % , 40 % , 86 % , 90 % , 77 %) respectively . Colistinand PolymyxinB showed highest percent of sensitivity (100%) in all isolates as shown in (Fig. 1).




FIGURE 1:The resistancepercentageofMDRA.*baumanni*to 12 antibiotics

Detection of bla_{OXA-23} also bla_{OXA-51} in A.buammanii using polymerase chain reaction (PCR):

Amplification of bla_{OXA-51} gene was found in all 22 (100%) A.baumanniiisolatesafteranalysisof thePCR product.Whereasebla_{OXA-23} genewas shownto beexpressedin18(81%)oftheparticipants "fig2, 3"




FIGURE 2 :The amplification results usingbla_{oxa51} primer in *Acinetobacterbaumannii* speciesfractionatedon1.5% agarosestainedwithEth.Br. M:100bpladder marker.Lanes1-22resemble353bp

PCRproducts.




FIGURE 3 :The amplification results using blaOXA-23 primer in *Acinetobacter baumannii* fractionated on 1.5% agarose stained with Eth.Br. M: 100bp ladder marker. All lanes were positive 501bp PCR products, except 3, 5, 18 also 20 were not carrying blaOXA-23.

DISCUSSION

From September (2020) to March (2021) 22 *A. baumannii* isolates were obtained from clinical samples of (burns, wounds, urine, blood and fluids). Biochemical measures such as sugar fermentation (+), citrate utilization (+), urease(-), motility (-), oxidative/fermentative glucose (O/F) test(-), oxidase (-), catalase(+), and growth potential at 37°C and 42°C (+) were used to identify *A. baumannii* isolates (10). The isolates were classified at the genus level using the VITEK 2 automated method (bioMérieux, France). However, it has been shown to be ineffective in distinguishing *Acinetobacter baumannii* from other bacteria such as *Acinetobacter nosocomialis*, *Acinetobacter pittii*, and *Acinetobacter calcoaceticus* (14). Presence of bla_{OXA-51} in all isolates was also investigated (FIGURE 1).

Antibiotic susceptibility testing:

22 carbapenem resistant *A. baumannii* were tested to show antibiotic susceptibility were (71.5 %) (68.75%). Infections caused by *Acinetobacter* spp. treated by carbapenem. This finding with close research published by (Hameed A. M. and Najeeb L.M., 2020) (15), that (68.75%) carbapenem resistant *A. baumannii* from 48 clinical strains were multidrug resistant.

Detection of bla_{OXA-23} and bla_{OXA-51} in *A. baumannii* by molecular assay :

MDRA *A. baumannii* clinical isolates have a high prevalence of bla_{OXA-23} according to PCR findings (81 %). *A. baumannii* has been shown to release OXA-23 in a number of republics, suggesting that this enzyme is commonly spread on the globe (16). Nosocomial outbreaks or sporadic cases of *Acinetobacter* containing OXA-23 were published in (Europe, Singapore, Australia, the United States, Algeria, Egypt, Libya, South Africa, Thailand, Tunisia, Iraq, and French Polynesia) this research by Kempf and Rolain (17). In *A. baumannii*, OXA-23 is the most commonly distributed class D enzyme in China and Korea (18). OXA-23-like enzymes have been identified as one of the key carbapenem resistance pathways in *Acinetobacter* spp. in Brazil. (19,20).

The bla_{OXA-51} gene has been described as being particularly specific for distinguishing *A. baumannii* at the

species level (21). The expression of blaOXA-51 genes was detected in all 22 isolates (100%) of *A. baumannii* by PCR, which is compatible with previous studies in Iraq. Mohammed S.M. (2020)(22) discovered the same thing in the city of Diyala. Another research in Anbar/IRAQ discovered blaOXA-51 gene in all CRAB isolates, suggesting that the blaOXA-51 gene is the most common mechanism for imipenem tolerance in *A. baumannii* isolates. (Hameed and Najeeb) (15). Anane et al., (2020) observed that blaOXA-51 was present in all isolates, while blaOXA-23 was present at 70% of isolates (22, 23).

Nonetheless, in countries other than Iraq, such as the United States, similar findings have been released (Bulgaria, China, Brazil, Afghanistan also Korea). (21) Both isolates contained the chromosomally encoded blaOXA-51 gene, corroborating previous observations and suggesting that the discovery of the blaOXA-51 gene may be used as a supplementary tool for recognizing *A. baumannii* at the species level in combination with other procedures (24).

CONCLUSION

We detect a high occurrence of blaOXA-51 and blaOXA-23 in multidrug resistance *A. baumannii* strains in Baquba Teaching Hospital, Diyala, Iraq. Due to the difficulty of selecting empirical medications for chronically sick people, there is a risk of additional hospitalization and related costs. Continuous research, as well as early identification of MDR *A. baumannii* isolates, is critical in order to prevent their dissemination inside the hospital setting.

ACKNOWLEDGMENTS

We thank all staff of Bacteriology laboratory at the Teaching Baquba Hospital in Baquba city also thank to all staff of microbiology lab. Biology department / College of science/ Diyala university /Iraq, for their kind assistance, Thanks to Dr. Zaid, ASCO Learning Center PCR unit to performed this work.

REFERENCES

1. A. Y. Peleg, H. Seifert, also D. L. Paterson, *Acinetobacter baumannii*: emergence of a successful pathogen, Clin. Microbiol. Res. vol. 21, no. 3, pp. 538–582, (2008).
2. H. Singh, P. Thangaraj, A. Chakrabarti. *Acinetobacter baumannii*: A brief account of mechanisms of multidrug resistance also current also future therapeutic management, J Clin Diagnostic Res.; 7(11):2602–5. (2013).
3. A. Bianco, et al. Control of carbapenem-resistant *Acinetobacter baumannii* outbreak in an intensive care unit of a teaching hospital in Southern Italy. BMC infectious diseases. 16, 747, (2016).
4. N.C. Gordon, D.W. Wareham. Multidrug-resistant *Acinetobacter baumannii*: mechanisms of virulence also resistance. Int J Antimicrob Agents. 35:219–26. (2010).
5. H. J. Kim, H.S. Kim, J.M. Lee, S.S. Yoon, & D. Yong, . Rapid Detection of *Pseudomonas aeruginosa* also *Acinetobacter baumannii* Harboring blaVIM-2, blaIMP-1 also blaOXA-23 Genes via Using Loop-Mediated Isothermal Amplification Methods. Ann Lab Med. 36, 15–22 (2016).
6. Q. Zhong, W. Xu, Y. Wu, H. Xu. Clonal spread of carbapenem non-susceptible *Acinetobacter baumannii* in an intensive care unit in a teaching hospital in China. Ann Lab Med. 32(6):413–9. (2012).
7. K. Bush, . Alarming β -lactamase-mediated resistance in multidrug-resistant Enterobacteriaceae. Current Opinion in Microbiol. 13, 558–564. (2010).
8. A. Opazo, M. Domínguez, H. Bello, S.G. Amyes, & G. González-Rocha. OXA-type carbapenemases in *Acinetobacter baumannii* in South America. J Infect Dev Ctries. 6, 311–316. (2012).
9. N. Yamamoto, et al. Clinical Specimen-Direct LAMP: A Useful Tool for the Surveillance of blaOXA-23-Positive Carbapenem-Resistant *Acinetobacter baumannii*. PloS one. 10, (2015).
10. B.A. Forbes, D.F. Sahn, A.S. Weissfeld. Study guide for Bailey & Scott's diagnostic microbiology. Mosby USA. (2007).
11. P.A. Wayne. Performance Standards for Antimicrobial Susceptibility Testing. 27th ed.: Clinical Laboratory Standards Institute. (2019).

12. K.E. SchimithBier , S.O. Luiz , M.C.Scheffer , et al. Temporal evolution of carbapenem-resistant *Acinetobacterbaumannii* in Curitiba, southern Brazil. *Am J Infect Control*. 38:308–14.(2010).
13. N.Woodford, M. J. Ellington, J. M. Coelho, J. F. Turton, M. E. Ward, S. Brown, S. G. B. Amyes, also D. M. Livermore. Multiplex PCR for genes encoding prevalent OXA carbapenemases in *Acinetobacter* spp. *Int. J. Antimicrob. Agents* 27:351-353.(2006).
14. V.A.Gundi , L. Dijkshoorn , S. Burignat , D. Raoult , B .La Scola . Validation of partial *rpoB* gene sequence analysis for the identification of clinically important also emerging *Acinetobacter* species. *Microbiology*. 55:2333-41.(2009).
15. A.M.Hameed also L.M. Najeeb . Molecular Detection of *blaOXA-51* in Carbapenem-resistant *Acinetobacterbaumannii* Isolated from Different Clinical Sources. *Medico-legal Update* . Vol. 20, No. 4:694-698(2020).
16. Y. Fu , J. Zhou ,H. Zhou , et al. Wide dissemination of OXA-23-producing carbapenem-resistant *Acinetobacterbaumannii* clonal complex 22 in multiple cities of China. *J Antimicrob Chemother*. 65:644-50.(2010).
17. M. Kempf also J.M. Rolain . Emergence of resistance to carbapenems in *Acinetobacterbaumannii* in Europe: clinical impact also therapeutic options. *Int J Antimicrob Agents*. 39:105-14.(2012)
18. S.S.Jean also P.R. Hsueh . High burden of antimicrobial resistance in Asia. *Int J Antimicrob Agents*. 37:291-5. (2011)
19. Carneiro M, Barbosa PI, Vespero EC, et al. Carbapenem-resistant OXA-23-producing *Acinetobacterbaumannii* isolates causing ventilator-associated pn20
20. F. Rossi . The challenges of antimicrobial resistance in Brazil. *Clin Infect Dis*. 52:1138-43.(2011).
21. Y. T. Lee , S. C. Kuo , M.C. Chiang , S. P. Yang , C.P. Chen , T.L. Chen , et al. Emergence of carbapenem resistant non-baumannii species of *Acinetobacter* harboring a *blaOXA-51*-like gene that is intrinsic to *A. baumannii*. *Antimicrob Agents Chemother*.56(2):1124–7. (2012) .
22. S.M. Mohammed . Occurrence of some Metallo- β - Lactamases genes in *Acinetobacterbaumannii* isolated from different samples clinical source .A Thesis of Master ,Diyala University. College of Science.
23. Y. A. Anane, T. Apalata, S. Vasaikar, G. Emily Okuthe, also S. Songca. Molecular Detection of Carbapenemase-Encoding Genes in Multidrug-Resistant *Acinetobacterbaumannii* Clinical Isolates in South Africa. *Int J Microbio*. Vol:2020 pp10 :(2020).
24. A. Howard, M. O'Donoghue, A. Feeney, also R. D. Sleator, *Acinetobacterbaumannii*, *Virulence*, vol. 3, no. 3, pp. 243–250, (2012).